Viking Therapeutics Inc. (VKTX) is advancing its efforts in the obesity treatment sector, with management highlighting a recent manufacturing agreement and plans to initiate Phase 3 obesity studies in the second quarter of 2025. The company also anticipates releasing data from its Phase 2a oral study in the second half of 2025, which could show weight loss results of 10% or higher. This news has led to expectations of significant price gains for VKTX, with a buy point target of 102, and comparisons drawn to Eli Lilly and Co. (LLY), which saw its market cap increase by over $100 billion following the release of data for its oral drug. Analysts have reviewed various reports on VKTX, with some expressing optimism about the company's revenue models. Even conservative projections suggest VKTX could achieve sales of $5 billion and profits of $3 billion, while more optimistic forecasts predict $10 billion in sales and $7 billion in profits. These projections draw comparisons to established pharmaceutical companies like Pfizer Inc. (PFE) and Merck & Co. Inc. (MRK). There is also mention of short interest in VKTX. Separately, Tesla Inc. (TSLA) has launched a new X account dedicated to its Tesla Semi, signaling potential developments in its electric truck division. This move has sparked speculation about an upcoming ramp-up in production and new product launches, with Tesla also advertising for a 'New Product' Launch Engineer. Tesla is also noted to be 'on the road' with its vehicles.